Intellia Therapeutics, Inc. (NTLA)

Intellia Therapeutics' stock has been impacted by positive Phase 3 results from its HAELO trial for Lonvo-z, leading to a surge in the stock price. Following these results, Intellia initiated a rolling BLA submission to the FDA for Lonvo-z. The stock experienced a pullback due to a dilutive public offering of common stock. The FDA lifted clinical holds on Intellia's Nex-z trials for transthyretin amyloidosis. Earnings reports and analyst ratings have also influenced the stock.

Intellia Therapeutics does not currently have commercialized products or services subject to demand seasonality. Its revenue is primarily derived from collaboration agreements, and its focus remains on research, development, and clinical trials.

Intellia Therapeutics is a clinical-stage biotechnology company focused on developing curative therapeutics using CRISPR-based gene-editing technologies. The company employs both in vivo and ex vivo gene editing approaches. Key in vivo product candidates include Lonvo-z, which is in the BLA submission phase for HAE, and Nex-z, in late-stage clinical trials for ATTR. The ex vivo programs utilize CRISPR to engineer human cells outside the body to treat conditions like cancer and autoimmune diseases. Intellia has collaborations with several companies to advance its pipeline.

Intellia Therapeutics is headquartered in Cambridge, Massachusetts, United States. Its primary operational and research base is located in Cambridge, although its clinical trials and collaborations may have a global reach.

Intellia Therapeutics' brand reputation has been shaped by its scientific advancements and clinical trial progress. The positive Phase 3 results for Lonvo-z significantly bolstered its reputation. The lifting of clinical holds on its Nex-z trials also contributed positively. A patient death incident in the past year, which led to a temporary clinical hold on Nex-z, would have negatively impacted its reputation, although the hold has since been lifted. Analyst sentiment is generally a "Moderate Buy," but with a wide range of price targets.

Intellia Therapeutics has significant institutional ownership, with institutional shareholders holding approximately 88.22% or 88.8% of the company's stock. Insiders hold around 1.80% to 33.40% of the shares, while retail investors hold a smaller percentage. Caribou Therapeutics Holdco LLC is the largest individual shareholder, owning 4.74% of the company's shares.